Novaremed AG

Novaremed AG is a privately held clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on innovating chronic pain management by developing effective and safe treatment options as an alternative to opioids. The company was founded in 2008 by Eli Kaplan, MD, who serves as Executive Chairman and who previously practiced medicine in Switzerland and spent more than 30 years in the pharmaceutical industry, particularly in oncology drug development. Novaremed's lead product is nispomeben (also referred to as NRD.E1), an orally active non-opioid small molecule with a novel mechanism of action. It has received FDA Fast Track Designation and is being studied in an NIH-sponsored Phase 2b clinical trial for the treatment of painful diabetic peripheral neuropathy (PDPN) as part of the NIH HEAL (Helping to End Addiction Long-term) initiative. The company's earlier-stage pipeline includes the clinical candidate MP-101 (Phase 2), which is being developed for the prevention of chemotherapy-induced peripheral neuropathy (CIPN). The company operates as a clinical-stage developer rather than a commercial manufacturer, with its activities centered on clinical trials, regulatory interactions, and licensing. In July 2022, Novaremed entered into an exclusive option and license agreement with NeuroFront for the non-opioid neuropathic pain treatment NRD.E1 for Greater China and Singapore. Novaremed has also published Phase 1 and Phase 2a study data for NRD.E1 and a pharmacological profile for MP-101. As a privately held company, Novaremed is not listed on any stock exchange. Its management team includes Eli Kaplan as Executive Chairman, Maurizio Rainisio as Head of Biometry and Board member, and Camilla Mittelholzer as Chief Scientific Officer and Head of R&D. The company's stated aim is to provide non-opioid alternatives for chronic pain, addressing a major unmet medical need amid the opioid crisis.

Novaremed AG was founded in 2008 by Eli Kaplan, MD, who serves as Executive Chairman. Kaplan brought extensive experience in the pharmaceutical industry, particularly in oncology drug development, having worked at Farmitalia Carlo Erba in Italy and Germany, and having founded a consulting firm, Seneb-Pharma, between 1994 and 1998. The company is headquartered in Basel, Switzerland, and operates as a privately held clinical-stage biopharmaceutical company. Novaremed's focus is on developing non-opioid treatments for chronic pain. Its lead product, nispomeben (also known as NRD.E1), is an orally active non-opioid small molecule with a novel mechanism of action. In June 2022, the company announced the publication of Phase 1 and Phase 2a study data with NRD.E1, demonstrating the potential of this investigational non-opioid pain treatment. In July 2022, Novaremed entered into an exclusive option and license agreement with NeuroFront for NRD.E1 for Greater China and Singapore. In January 2023, Novaremed announced the publication of the pharmacological profile of MP-101, a clinical development candidate for the prevention of chemotherapy-induced peripheral neuropathy (CIPN). By May 2025, the company announced completion of enrollment in an NIH-sponsored Phase 2b study with non-opioid NRD.E1 for the treatment of chronic pain associated with diabetic peripheral neuropathy (PDPN). In September 2025, Novaremed announced the completion of all patient visits in that NIH-funded Phase 2b trial. The trial is part of the NIH HEAL (Helping to End Addiction Long-term) initiative, and nispomeben has received FDA Fast Track Designation. The company's pipeline includes nispomeben for PDPN and MP-101 (Phase 2) for CIPN. Novaremed continues to advance its clinical programs with the goal of providing safe and effective alternatives to opioids for chronic pain management.

• 2025

  Completion of enrollment in NIH-sponsored Phase 2b study of NRD.E1 for PDPN.

• 2025

  Completion of all patient visits in NIH-funded Phase 2b trial of nispomeben for PDPN.

• 2023

  Publication of pharmacological profile of MP-101 for CIPN prevention.

• 2022

  Publication of Phase 1 and Phase 2a study data with NRD.E1.

• 2022

  Exclusive option and license agreement with NeuroFront for NRD.E1 in Greater China and Singapore.

• 2008

  Novaremed founded by Eli Kaplan, MD.

Clinical-stage biopharmaceutical company developing non-opioid alternatives for chronic pain management.

• Nispomeben (NRD.E1)

  Orally active non-opioid small molecule with a novel mechanism of action, in Phase 2b for painful diabetic peripheral neuropathy (PDPN). FDA Fast Track Designation.

• MP-101

  Clinical candidate (Phase 2) for the prevention of chemotherapy-induced peripheral neuropathy (CIPN).

1. 1Home | Novaremednovaremed.com
2. 2About | Novaremednovaremed.com
3. 3Novaremed AG (Switzerland) - Wikidatawikidata.org
4. 4Home | Novaremednovaremed.com